Hims vs MEDVi: Which GLP-1 Provider Is Better?
By Iacob Pastina, Independent Researcher
Hims beats MEDVi overall, scoring 7.9/10 vs 7.7/10. Hims is more affordable at $175/mo vs $299/mo. Choose Hims for men who want glp-1 access from a well-known, publicly traded. Choose MEDVi for users who want a low entry price with oral and injectable co.
A side-by-side comparison of Hims and MEDVi covering pricing, scores, medication types, insurance, and more to help you decide.
Hims
#12 of 40One of the largest and most recognized men's telehealth platforms in the US, offering compounded GLP-1 medications with a polished app experience and strong brand trust.
Visit HimsMEDVi
#21 of 40Compounded GLP-1 platform offering both oral and injectable options with flexible dosing and affordable pricing.
Visit MEDVi| Feature | Hims | MEDVi |
|---|---|---|
| Our Score | 7.9/10 | 7.7/10 |
| Starting Price | $175/mo | $299/mo |
| Medication Type | Compounded | Compounded |
| Insurance Accepted | No | No |
| Best For | Men who want GLP-1 access from a well-known, publicly traded telehealth brand | Users who want a low entry price with oral and injectable compounded options |
| Ranking | #12 | #21 |
Pros & Cons Compared
Hims
Pros
- +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
- +Polished app and web experience — one of the best user interfaces in men's telehealth
- +$199/mo all-inclusive for compounded semaglutide with consultations and free shipping
- +Massive brand recognition and extensive customer support infrastructure
Cons
- −Pivoted away from some compounded formulations after FDA crackdown — medication availability can shift
- −Compounded only — no brand-name Wegovy or Zepbound through the platform
- −Generic support experience — large patient volume means less personalized attention
- −Higher price than competitors like TrimRx ($179) or Enhance MD ($115) for a similar compounded product
MEDVi
Pros
- +One of the few compounded providers offering both oral tablets and injectable semaglutide
- +Micro-dosing options available — can start at sub-standard doses for patients concerned about side effects
- +Sleek onboarding experience with clear progress tracking through their patient portal
- +$179/mo is competitive for a platform with both oral and injectable compounded formulations
Cons
- −Compounded medications only — no path to brand-name Wegovy or Zepbound through their platform
- −No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms
Our Verdict
Hims edges out MEDVi with a score of 7.9/10 vs 7.7/10. If budget is your priority, Hims starts at $175/mo compared to MEDVi's $299/mo. Choose Hims if you want: men who want glp-1 access from a well-known, publicly traded telehealth brand. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.